Moderna’s efforts to develop a range of mRNA vaccines for influenza have been bolstered with funding of up to $750 million from investment firm Blackstone Life Sciences.
If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics
Clasp Therapeutics has burst onto the T-cell engager (TCE) scene with $150 million in funding for a platform that aims to improve the safety of the class, which is current
Our latest round-up of funding rounds in the digital health category features updates from Healthee, Aktiia, Moxe Health, Eleanor Health, Tava Health, BrainCheck, and Redi
Munich-based antibody-drug conjugate (ADC) specialist Tubulis has completed a sizeable Series B2 financing that shows sustained investor appetite for the ADC category, par
Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.